Pneumonia Therapeutics Market 2020 By Regional Trend & Growth Forecast To 2026

Pneumonia Therapeutics Market report offers in-depth analysis of the industry size, share, major segments, and different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and industry challenges.

A significant rise in the cases of community-acquired and ventilator-associated bacterial pneumonia is expected to majorly drive the pneumonia therapeutics market size through the forthcoming years. Subsequently, ongoing medical trials towards the development of new drug molecules and vaccines for pneumonia will push the industry size. Pneumonia is a severe disease that infects one or even both lungs, causing them to be filled with fluid.

Consistent growth in the global population coupled with the increasing demographic of individuals that are more vulnerable to infections like pneumonia, including people aged 65 and above as well as children aged two years or less, would majorly impact industry growth. The aged population is highly vulnerable to this disease as their immune systems are weak and they cannot tackle the infection on their own. This shifting population trend is subsequently indicating that pneumonia is likely to emerge as a severe global health issue, creating more opportunities for pneumonia therapeutics.

Request for a sample copy of this report @ https://www.decresearch.com/request-sample/detail/2029

In terms of the distribution channel, the market is characterized by hospital pharmacies, retail pharmacies, and online pharmacies. Of these, the ease in accessibility of online pharmacies is projected to fuel their expansion over the coming years. Moreover, introduction of additional promotional discounts by online pharmacies are further expected to stimulate the segment share. In fact, the online pharmacies segment is projected to hold about 16% of the overall industry share by the end of the forthcoming timeframe.

On the regional forefront, in 2019, the Europe pneumonia therapeutics industry accounted for an overall industry valuation of over $375 million. The regional segment is likely to witness remunerative growth trend through the forecast timeframe. This growth is attributed to the region’s highly-developed healthcare infrastructure and the increasing use of pneumonia therapeutics in the region.

Key market players are making active efforts to discover new treatments to tackle this disease in a more effective and quick manner. Taking June 2020 for instance, the Recarbrio was authorized by the U.S. FDA (Food and Drug Administration) for the treatment of ventilator-linked bacterial pneumonia and hospital-acquired bacterial pneumonia in adults. The FDA granted the Recarbrio application a QIDP (Qualified Infectious Disease Program) designation, which is only given to antifungal and antibacterial drugs that are intended to effectively treat life-threatening or other serious infections under the GAIN (Generating Antibiotic Incentives Now) title of FDA Safety & Innovation Act.

The competitive landscape of the global pneumonia therapeutics market is inclusive of players such as Sanofi, Pfizer, Novartis, Mylan, Merck, Lupin Pharmaceuticals, GlaxoSmithKline, Cipla, Bayer, AstraZeneca, Allergan, and Abbott Laboratories among others. 

Browse full table of contents (TOC) of this report @ https://www.decresearch.com/toc/detail/pneumonia-therapeutics-market

Partial Chapter of the Table of Content 

Chapter 4. Pneumonia Therapeutics Market, By Drug Class

4.1. Key segment trends

4.2. Antibacterial drugs

4.2.1.  Antibacterial drugs market, by region, 2015 - 2026, (USD Million)

4.2.2.  Macrolide

4.2.2.1.    Macrolide market, by region, 2015 - 2026, (USD Million)

4.2.3.  Quinolones

4.2.3.1.    Quinolones market, by region, 2015 - 2026, (USD Million)

4.2.4.  Others

4.2.4.1.    Others market, by region, 2015 - 2026, (USD Million)

4.3. Antiviral drugs

4.3.1.  Antiviral drugs market, by region, 2015 - 2026, (USD Million)

4.4. Antifungal drugs

4.4.1.  Antifungal drugs market, by region, 2015 - 2026, (USD Million)

Chapter 5. Pneumonia Therapeutics Market, By Age Group

5.1. Key segment trends

5.2. Pediatric

5.2.1.  Pediatric market by region, 2015 - 2026 (USD Million)

5.3. Adult

5.3.1.  Adult market, by region, 2015 - 2026, (USD Million)

5.4. Geriatric

5.4.1.  Geriatric market by region, 2015 - 2026 (USD Million)